Alle Storys
Folgen
Keine Story von Helsinn Healthcare SA mehr verpassen.

Helsinn Healthcare SA

Helsinn Healthcare Licenses a Supportive Care Product from Roche

Biasca, Switzerland (ots)

HELSINN HEALTHCARE SA, a Swiss
pharmaceutical group, and ROCHE today announced the signing of a
licensing agreement, granting HELSINN HEALTHCARE the worldwide rights
for the patented, phase II product, NETUPITANT. Netupitant is a
potent and selective NK-1 receptor antagonist, developed as NKE by
Roche, for the prevention of chemotherapy-induced nausea and vomiting
(CINV).
"We are delighted to strengthen our long lasting partnership with
Roche and enter into this new agreement for Netupitant." said Enrico
Braglia, Managing Director of HELSINN HEALTHCARE SA, "Our successful
collaboration with Roche in the anti-emetic arena started in 1998
with the licensing of Palonosetron (AloxiÒ), a strong and long acting
5-HT3 receptor antagonist for the prevention of CINV and PONV (post
operative nausea and vomiting). The new acquisition of Netupitant is
an excellent opportunity to boost our AloxiÒ franchise. Helsinn
intends to complete the development of Netupitant in order to bring
to the physicians and their patients a novel and effective emesis
treatment".
"Helsinn has significant experience in developing emesis products
for oncology patients. Roche is pleased to continue our relationship
with Helsinn through their further development of Netupitant," said
Peter Hug, Roche's Head of Pharma Partnering.
About NK-1 receptor antagonists
NK-1 receptor antagonists are antiemetics that work by blocking
the action of neurokinin-1 (Substance P), a natural substance in the
brain that causes emesis. In the clinic, it has been demonstrated
that NK-1 receptor antagonists, administered in conjunction with a
5-HT3 receptor antagonist, are significantly more effective in the
control of both acute and delayed nausea and vomiting compared with
5-HT3 receptor antagonists alone.
About HELSINN HEALTHCARE
HELSINN HEALTHCARE SA is a privately owned pharmaceutical group
with headquarters in Switzerland. HELSINN's core business is the
licensing of pharmaceuticals in niche therapeutic areas. The
company's business strategy is to in-license early-stage new chemical
entities and complete their development from the performance of
pre-clinical/clinical studies and CMC development to the attainment
of market approvals in strategic markets (U.S. and Europe). HELSINN's
products are eventually out-licensed to its marketing partners for
distribution. The active pharmaceutical ingredients and the finished
dosage forms are manufactured at HELSINN's cGMP facilities and
supplied worldwide to its customers. For more information about
HELSINN, please visit www.helsinn.com.
Contact person HELSINN:
Alex Bossi, Director BD & Licensing-in
Tel.: +41/91/985'21'21
E-Mail:   info-hhc@helsinn.com

Weitere Storys: Helsinn Healthcare SA
Weitere Storys: Helsinn Healthcare SA